The multicenter, prospective Stimulation Therapy for Apnea Reduction (STAR) trial was conducted at 22 medical centers in the United States and Europe, and is the first to evaluate the use of upper airway stimulation for sleep apnea.
This image shows how the Inspire® Upper Airway Stimulation Therapy device works.
OSA, which affects more than 8 million men and 4 million women in the U.S. and is twice as common in men, is characterized by repeated episodes of upper airway collapse during sleep, due to narrowing or blockage.
Patients with OSA stop breathing, known as apnea, frequently during sleep, often for a minute or longer, and over half of those with OSA are overweight. Repeated episodes of apnea can lead to daytime fatigue, and increase a person's risk for heart attack, stroke, high blood pressure and even death.
Treatments for OSA include weight loss, upper airway surgeries, oral appliances, and continuous positive airway pressure (CPAP), which is considered the primary treatment for OSA.
"While CPAP is a successful treatment when used on a regular basis, as many as half of the patients who have been prescribed CPAP are unable to use it regularly, largely due to discomfort with the mask and/or the lack of desire to be tethered to a machine," said Patrick Strollo, M.D., professor of medicine and clinical and translational science at the University of Pittsburgh School of Medicine, medical director of the UPMC Sleep Medicine Center, and lead author of the study. "The results of this trial show a huge potential for a new and effective treatment that can help millions of patients."
"Inspire UAS therapy differs from other traditional sleep apnea devices and surgical procedures in that it targets the muscle tone of the throat rather than just the anatomy," noted Ryan Soose, M.D., director of the UPMC Division of Sleep Surgery and assistant professor at the University of Pittsburgh School of Medicine, Department of Otolaryngology. "Two thirds of patients using the Inspire UAS therapy device had successful control of their OSA although even more reported improvement in snoring, daytime sleepiness and quality of life measures. Eighty-six percent of patients were still using the device every night at the one year mark, which compares very favorably to CPAP."
From 724 candidates initially screened, the STAR trial implanted and prospectively evaluated 126 moderate-to-severe OSA patients who had difficulty using or adhering to CPAP therapy:
•83 percent of the participants were men, the mean age was 54.5 years, and the mean body-mass index was 28.4.
•All patients underwent surgery to implant the device. The device stimulates the nerve of the tongue during sleep, thereby enlarging and stabilizing the airway and improving control of breathing.
•Surgical implantation of the upper-airway stimulation system was performed by otolaryngologists at 22 academic and private centers, including Ryan Soose, M.D., of UPMC Ear, Nose and Throat specialists.
•The device was implanted in three areas: a stimulation electrode was placed on the hypoglossal nerve, which provides innervation to the muscles of the tongue; a sensing lead was placed between rib muscles to detect breathing effort; and a neurostimulator was implanted in the upper right chest, just below the clavicle bone.
•Patients used a "controller" to turn on the device at night, so it is only used when the patient sleeps. The Inspire UAS therapy device is designed to sense breathing patterns and deliver mild stimulation to a patient's airway muscles to keep the airway open during sleep.
•Using various sleep-disorder measuring systems, patients were found to experience 68 to 70 percent fewer sleep-apnea episodes per hour.
"My short-term memory has improved significantly, and the surgery has made a huge difference in my quality of life," said Kathy Gaberson, one of the study participants who used the Inspire therapy. "My apnea episodes went from 23 times an hour to just two."
This study was funded by Inspire Medical Systems.
Dr. Soose is a consultant for Inspire Medical Systems.
Co-investigators include researchers from University Hospital, Mannheim; Intersom K.ln, Cologne; Sint Lucas Hospital, Amsterdam; North Memorial Sleep Health Center, Maple Grove; Paparella Ear, Head, and Neck Institute; St. Cloud Ear, Nose, and Throat; the University of South Florida College of Medicine; the St. Petersburg Sleep Disorders Center; the University of Cincinnati; the Medical College of South Carolina, Charleston; the Medical College of Wisconsin; Antwerp University Hospital; the University of Antwerp; the Borgess Medical Center; the Louis Stokes Cleveland Veterans Affairs Medical Center; and, Case Western Reserve University.About the University of Pittsburgh Schools of the Health Sciences
http://www.upmc.com/mediaContact: Cristina Mestre
Cristina Mestre | EurekAlert!
Artificial intelligence can speed up the detection of stroke
31.03.2020 | University of Turku
Thermopiles for non-contact temperature measurement at humans
31.03.2020 | CiS Forschungsinstitut für Mikrosensorik GmbH
The bacteria that cause tuberculosis need iron to survive. Researchers at the University of Zurich have now solved the first detailed structure of the transport protein responsible for the iron supply. When the iron transport into the bacteria is inhibited, the pathogen can no longer grow. This opens novel ways to develop targeted tuberculosis drugs.
One of the most devastating pathogens that lives inside human cells is Mycobacterium tuberculosis, the bacillus that causes tuberculosis. According to the...
An international team with the participation of Prof. Dr. Michael Kues from the Cluster of Excellence PhoenixD at Leibniz University Hannover has developed a new method for generating quantum-entangled photons in a spectral range of light that was previously inaccessible. The discovery can make the encryption of satellite-based communications much more secure in the future.
A 15-member research team from the UK, Germany and Japan has developed a new method for generating and detecting quantum-entangled photons at a wavelength of...
Together with their colleagues from the University of Würzburg, physicists from the group of Professor Alexander Szameit at the University of Rostock have devised a “funnel” for photons. Their discovery was recently published in the renowned journal Science and holds great promise for novel ultra-sensitive detectors as well as innovative applications in telecommunications and information processing.
The quantum-optical properties of light and its interaction with matter has fascinated the Rostock professor Alexander Szameit since College.
Researchers at the University of Zurich show that different stem cell populations are innervated in distinct ways. Innervation may therefore be crucial for proper tissue regeneration. They also demonstrate that cancer stem cells likewise establish contacts with nerves. Targeting tumour innervation could thus lead to new cancer therapies.
Stem cells can generate a variety of specific tissues and are increasingly used for clinical applications such as the replacement of bone or cartilage....
An international research team led by Kiel University develops an extremely porous material made of "white graphene" for new laser light applications
With a porosity of 99.99 %, it consists practically only of air, making it one of the lightest materials in the world: Aerobornitride is the name of the...
26.03.2020 | Event News
23.03.2020 | Event News
03.03.2020 | Event News
01.04.2020 | Physics and Astronomy
01.04.2020 | Life Sciences
01.04.2020 | Physics and Astronomy